After nearly two decades, a new therapeutic agent, canagliflozin, received regulatory approval to prevent loss of kidney function, end-stage kidney disease, hospitalization for heart failure and cardiovascular death in patients with diabetic kidney disease. Nonetheless, the residual risk of kidney disease progression and complications remains high, underlining the importance of ongoing therapeutic development.
A sodium–glucose cotransporter 2 (SGLT2) inhibitor is now indicated to preserve kidney function and to prevent end-stage kidney disease (ESKD), hospitalization for heart failure and cardiovascular death in diabetic kidney disease (DKD).
Endothelin blockade is another promising therapeutic approach for DKD when applied after safety assessment for volume retention, irrespective of initial albuminuria reduction.
Glucagon-like peptide 1 (GLP1) receptor agonists are emerging as effective agents for glycaemic control, atherosclerotic cardiovascular disease risk reduction and estimated glomerular filtration rate (eGFR) preservation, even in patients with advanced stages of DKD.
Vitamin D and omega-3 fatty acids are ineffective for preventing loss of kidney function or ESKD in patients with DKD.
Allopurinol did not slow measured GFR decline despite effective uric acid lowering in patients with type 1 diabetes and early DKD.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Heerspink, H. J. L. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393, 1937–1947 (2019).
Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).
Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicenter, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018).
Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).
de Boer, I. H. et al. Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial. JAMA 322, 1899–1909 (2019).
Doria, A. et al. Preventing early renal loss in diabetes (PERL) study: outcome of a 3-year trial of serum uric acid reduction with allopurinol [abstract FR-OR 137]. ASN Kidney week https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3274268 (2019).
The author has consulted for Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca, Gilead, Goldfinch Bio, Novo Nordisk and Bayer.
About this article
Cite this article
Tuttle, K.R. The landscape of diabetic kidney disease transformed. Nat Rev Nephrol 16, 67–68 (2020). https://doi.org/10.1038/s41581-019-0240-6